Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor

Experimental Dermatology

Volumn 21, Issue 4, 2012, Pages 301-304

  Pletz, Nadin ^a   Schön, Margarete ^a   Ziegelbauer, Karl ^b   Emmert, Steffen ^a   Liu, Ningshu ^b   Dobbelstein, Matthias ^a   Schön, Michael P ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Chemoresistance; IKK; Melanoma; NF B; Small molecule

Indexed keywords

BAY 32 5915; DOXORUBICIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE INDUCTION; GENE PRODUCT; HUMAN; HUMAN CELL; IN VIVO STUDY; LETTER; MELANOMA CELL; PROTEIN FOLDING; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; GENE EXPRESSION; HUMANS; I-KAPPA B KINASE; MELANOMA; NF-KAPPA B; OXAZINES; OXYQUINOLINE; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84858441448     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2012.01440.x     Document Type: Letter

References (24)

1. Das K C, White C W. J Biol Chem 1997: 272: 14914-14920.
2. Soengas M S, Lowe S W. Oncogene 2003: 22: 3138-3151.
3. Karin M. Nature 2006: 441: 431-436.
4. Schön M, Wienrich B G, Kneitz S et al. J Natl Cancer Inst 2008: 100: 862-875.
5. Beinke S, Ley S C. Biochem J 2004: 382: 393-409.
6. Amschler K, Schön M P, Pletz N et al. J Invest Dermatol 2010: 130: 1073-1086.
7. Gangadharan C, Thoh M, Manna S K. J Cell Biochem 2009: 107: 203-213.
8. Palm C, Bjork O, Bjorkholm M et al. Anticancer Drugs 2001: 12: 859-864.
9. Bednarski B K, Baldwin A S Jr, Kim H J. PLoS ONE 2009: 4: e6992.
10. Murata T, Shimada M, Sakakibara S et al. Bioorg Med Chem Lett 2003: 14: 4019-4022.
11. Ziegelbauer K G F, Lukacs N W, Berlin A et al. Br J Pharmacol 2005: 145: 178-192.
12. Amiri K I, Richmond A. Cancer Metastasis Rev 2005: 24: 301-313.
13. Basseres D S, Baldwin A S. Oncogene 2006: 25: 6817-6830.
14. Colton S L, Xu X S, Wang Y A et al. J Biol Chem 2006: 281: 27117-27125.
15. Lal S, Mahajan A, Chen W N et al. Curr Drug Metab 2010: 11: 115-128.
16. Pommier Y, Leo E, Zhang H et al. Chem Biol 2010: 17: 421-433.
17. Wu Z H, Shi Y, Tibbetts R S et al. Science 2006: 311: 1141-1146.
18. Dejardin E. Biochem Pharmacol 2006: 72: 1161-1179.
19. Adli M, Merkhofer E, Cogswell P et al. PLoS ONE 2010: 5: e9428.
20. Chariot A. Trends Cell Biol 2009: 19: 404-413.
21. Liu B, Zhu F, Xia X et al. Cell Cycle 2009: 8: 527-531.
22. O'Mahony A, Lin X, Geleziunas R et al. Mol Cell Biol 2000: 20: 1170-1178.
23. Perkins N D. Nat Rev Mol Cell Biol 2007: 8: 49-62.
24. Yang J, Pan W H, Clawson G A et al. Cancer Res 2007: 67: 3127-3134.